carfilzomib / Generic mfg.  >>  Phase 2
Welcome,         Profile    Billing    Logout  

103 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
carfilzomib / Generic mfg.
2010-021111-17: A MULTICENTER, OPEN LABEL PHASE II STUDY OF CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS

Not yet recruiting
2
53
Europe
Carfilzomib, PR-171, Tablet, Powder and solvent for solution for injection, ENDOXAN BAXTER*50CPR RIV 50MG, SOLDESAM
HOVON Foundation
newly diagnosed multiple myeloma patients
 
 
NCT01346787: Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients

Checkmark ASH 2013
Nov 2013 - Nov 2013: ASH 2013
Completed
2
58
Europe
CARFILZOMIB, CYCLOPHOSPHAMIDE, DEXAMETHASONE
European Myeloma Network, Fondazione EMN Italy Onlus
Multiple Myeloma
10/12
05/23
2014-000782-53: This protocol is a phase II randomized, multicenter study designed to assess the safety and the efficacy of different carfilzomib combinations in newly diagnosed MM patients eligible for autologous transplantation (ASCT). Questo protocollo è uno studio di fase II randomizzato, multicentrico, per valutare la sicurezza e l'efficacia di differenti combinazioni di Carfilzomib in pazienti con nuova diagnosi di mieloma multiplo (MM), eleggibili al trapianto autologo (ASCT)

Ongoing
2
477
Europe
Carfilzomib, REVLIMID 5mg, REVLIMID 10 mg, REVLIMID 25 mg, PR-171, Powder for solution for injection, Capsule, hard, REVLIMID, REVLIMID 10mg, REVLIMID 25 mg
Università degli Studi di Torino-Dipartimento di Biotecnologie Molecolari e Scienze della Salute, Onix Therapeutics, Inc., Celgene Pharmaceuticals
NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) PATIENTS ELEGIBLE FOR AUTOLOGOUS TRANSPLANT Pazienti affetti da Mieloma Multiplo (MM) alla diagnosi, eleggibili al trapianto autologo, NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) PATIENTS ELEGIBLE FOR AUTOLOGOUS TRANSPLANT Pazienti affetti da Mieloma Multiplo (MM) alla diagnosi, eleggibili al trapianto autologo, Diseases [C] - Cancer [C04]
 
 
2013-003265-34: Pomalidomide combined with Carfilzomib and Dexamethasone (PCd) for induction and consolidation followed by Pomalidomide combined with Dexamethason vs Pomalidomide maintenance for patients with Multiple Myeloma in progression after prior 1st line treatment with Lenalidomide and Bortezomib. Inductie en consolidatie behandeling met Pomalidomide gecombineerd met Carfilzomib en dexamethason, gevolgd door onderhoudsbehandeling met Pomalidomide of Pomalidomide en dexamethason voor patiënten met Multipel Myeloom in progressie na een eerstelijns behandeling met Lenalidomide en Bortezomib

Ongoing
2
222
Europe, RoW
Carfilzomib, pomalidomide, Dexamethasone, [NA], Solution for injection, Capsule, hard, Tablet, Imnovid 1 mg, Imnovid 2 mg, Imnovid 3 mg, Imnovid 4 mg
HOVON Foundation, Stichting Hemato-Oncologie voor Volwassenen Nederland (Hovon), HOVON, Dutch Cancer Society, Celgene International, Amgen Ltd, Dutch cancer society, Onyx Pharmaceuticals
Multiple Myeloma Multiple Myeloom, Multiple Myeloma Multiple Myeloom, ziekte van Kahler, Diseases [C] - Cancer [C04]
 
 
2013-005157-75: Carfilzomib and lenalidomide-based treatment for younger and elderly newly diagnosed primary plasma cell leukemia patients

Ongoing
2
116
Europe, RoW
Kyprolis, Revlimid 5mg, Revlimid 10mg, Revlimid 15mg, Revlimid 25mg, N/A, Lyophilisate for solution for injection, Capsule, hard, Kyprolis, Revlimid 5mg, Revlimid 10mg, Revlimid 15mg, Revlimid 25mg
HOVON Foundation, HOVON, Dutch Cancer Society, Dutch Cance Society, HOVON
Primary plasma cell leukemia, Primary plasma cell leukemia, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2009-014922-40: Carfilzomib in combination with Thalidomide and Dexamethasone for remission induction and consolidation of Multiple Myeloma at first presentation

Ongoing
2
50
Europe
CARFILZOMIB, PR-171,
Erasmus MC, Onyx pharmaceuticals
Multiple myeloma at first presentation Multipel myeloom
 
 
2012-001320-36: A phase II randomised trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) compared to cyclophosphamide, velcade and dexamethasone (CVD)for first relapse or primary refractory mutiple myeloma patients.

Ongoing
2
300
Europe
Carfilzomib, Cyclophosphamide, Dexamethasone, Velcade, Dexamethasone, Velcade, Dexamethasone, Velcade
University of Leeds, Myeloma UK
multiple myeloma at the first relaspe of primary refractory disease stage
 
 
2012-005804-16: Front-line therapy with Carfilzomib, Lenalidomide, and Dexamethasone (CRd) induction followed by autologous stem cell transplantation, CRd consolidation and Lenalidomide maintenance in Newly Diagnosed Multiple Myeloma Patients ≤65 years old : a phase II study of the Intergroupe Francophone du Myélome (IFM) Traitement de première ligne par Carfilzomib, Lenalidomide et Dexamethasone (CRd) en induction suivi par une autogreffe de cellules souches, un traitement de consolidation par CRd et un entretien par Lenalidomide chez les patients de ≤65 ans atteints de Myélome Multiple de novo : une étude de phase II de l’Intergroupe Francophone du Myélome (IFM)

Ongoing
2
46
Europe
CARFILZOMIB, REVLIMID (LENALIDOMIDE) 25mg, CARFILZOMIB, REVLIMID (LENALIDOMIDE) 5mg, REVLIMID (LENALIDOMIDE) 25mg, CARFILZOMIB, REVLIMID (LENALIDOMIDE) 5mg
CHU de Toulouse, Onyx, Celgene
Multiple Myeloma Myelome Multiple
 
 
NCT01559935: Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma

Active, not recruiting
2
74
US
carfilzomib, Dexamethasone, DECADRON®, Clarithromycin, Biaxin, Lenalidomide, Revlimid
Weill Medical College of Cornell University, Onyx Therapeutics, Inc.
Multiple Myeloma
06/16
03/25
FORTE, NCT02203643: Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT or 12 Cycles of Carf Combined With Dex and Len for Patients Eligible for ASCT With Newly Diagnosed Multiple Myeloma.

Active, not recruiting
2
477
Europe
Carfilzomib, Cyclophosphamide, Lenalidomide, Revlimid, Dexamethasone
Mario Boccadoro
MULTIPLE MYELOMA (MM)
10/16
10/33
2016-003105-33: Carfilzomib and lenalidomide-based treatment for younger and elderly newly diagnosed primary plasma cell leukemia patients Trattamento con carfilzomib e lenalidomide per i pazienti giovani e anziani affetti da leucemia plasmacellulare primaria alla diagnosi

Ongoing
2
116
Europe
Carfilzomib, REVLIMID, Revlimid, L01XX45, Solution for infusion, Capsule, hard, REVLIMID - 5 MG CAPSULA RIGIDA - USO ORALE BLISTER (PCTFE/PVC/ALU) 21 CASPULE, REVLIMID - 10 MG CAPSULA RIGIDA - USO ORALE BLISTER (PCTFE/PVC/ALU) 21 CAPSULE, REVLIMID - 15 MG CAPSULA RIGIDA - USO ORALE BLISTER (PCTFE/PVC/ALU) 21 CAPSULE, REVLIMID - 25 MG CAPSULA RIGIDA - USO ORALE BLISTER (PCTFE/PVC/ALU) 21 CAPSULE
HOVON, Celgene International, Onyx Pharmaceuticals
Primary plasma cell leukemia Leucemia Plasma Cellulare, Primary plasma cell leukemia Leucemia Plasma Cellulare, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2017-000586-72: Kyprolis-Revlimid-dexamethasone consolidation treatment in myeloma patients with a positive PET-CT after standard first line treatment. A phase II study

Ongoing
2
50
Europe
dexamethasone, Concentrate and solvent for concentrate for solution for infusion, Kyprolis
Oslo University Hospital, Nordic Myeloma Study Group (NMSG)
Multiple Myeloma, Multiple Myeloma, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2016-004778-16: Use of a novel chemotherapeutic regimen in an attempt to eradicate residual myeloma disease after a first autologous stem cell Transplantation. Einsatz einer neuen Kombinationschemotherapie mit dem Ziel, nach einer ersten autologen Stammzelltransplantation verbleibende Reste einer Myelomerkrankung zu eradizieren.

Ongoing
2
41
Europe
Lenalidomide, Fortecortin, CC-5013, -, Powder for solution for infusion, Capsule, hard, Tablet, Kyprolis, REVLIMID 25 mg, Fortecortin
Department of Medicine I, Ordensklinikum Linz, Elisabethinen Hospital Linz, Amgen (Europe) GmbH
Multiple Myeloma Multiples Myelom, A special type of bone marrow cancer Eine Form des Knochenmarkskrebses, Diseases [C] - Cancer [C04]
 
 
NCT01816971: Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

Checkmark EHA 2014
May 2014 - May 2014: EHA 2014
Active, not recruiting
2
76
Canada, US
dexamethasone, Aeroseb-Dex, Decaderm, Decadron, DM, DXM, carfilzomib, Kyprolis, PR-171, lenalidomide, CC-5013, IMiD-1, Revlimid, autologous hematopoietic stem cell transplantation, laboratory biomarker analysis
University of Chicago, National Cancer Institute (NCI)
Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
04/18
12/26
ACTRN12615000934549: A multicentre single arm study of carfilzomib-thalidomide-dexamethasone (CarTD) for newly diagnosed transplant-eligible multiple myeloma (MM) patients refractory to initial bortezomib-based induction therapy

Active, not recruiting
2
50
 
Australiasian Leukaemia and Lymphoma Group, Onyx Pharmaceuticals Inc., a subsidiary of Amgen, Inc.
Multiple Myeloma
 
 
GEM-CESAR, NCT02415413 / 2014-002948-40: Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma

Active, not recruiting
2
90
Europe
carfilzomib, Lenalidomide, Dexamethasone, Melphalan
PETHEMA Foundation, Celgene Corporation, Amgen
Smoldering Multiple Myeloma
07/18
06/27
2018-000540-25: Carfilzomib + Lenalidomide +Dexamethasone for BTK inhibitors relapsed-refractory or intolerant mantle cell lymphomas Terapia di salvataggio ( Carfilzomib + Lenalidomide +Desametasone) per linfomi mantellari ricaduti, refrattari o intolleranti a trattamento con inibitori di BTK

Not yet recruiting
2
59
Europe
REVLIMID/LENALIDOMIDE, KRYPOLIS, [IMP1 - 5 MG], [IMP2], [IMP3- 10 MG], [IMP4 - 25 MG], Capsule, hard, Powder for solution for infusion, REVLIMID, KYPROLIS, REVLIMID - 15 MG CAPSULA RIGIDA - USO ORALE BLISTER (PCTFE/PVC/ALU) 21 CAPSULE
FONDAZIONE ITALIANA LINFOMI ONLUS, CELGENE, AMGEN
BTK inhibitors relapsed-refractory or intolerant mantle cell lymphomas Linfomi mantellari ricaduti, refrattari o intolleranti a trattamento con inibitori di BTK, BTK inhibitors relapsed-refractory or intolerant mantle cell lymphomas Linfomi mantellari ricaduti, refrattari o intolleranti a trattamento con inibitori di BTK, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2019-001027-12: Multicenter Open label Phase 2 study of Isatuximab plus Pomalidomide and Dexamethasone with Carfilzomib in Relapsed or Refractory Multiple Myeloma

Not yet recruiting
2
90
Europe
Pomalidomide, Carfilzomib, Isatuximab, Pomalidomide, Carfilzomib, Isatuximab, Capsule, Powder for solution for infusion, Solution for injection, Pomalidomide, Carfilzomib, Isatuximab
CHU de Poitiers, CHU de Poitiers
Multiple myeloma, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
Cardamon, NCT02315716 / 2014-000506-35: Carfilzomib/Cyclophosphamide/Dexamethasone With Maintenance Carfilzomib in Multiple Myeloma

Active, not recruiting
2
281
Europe
Autologous Stem Cell Transplant (ASCT), Consolidation with 4 cycles of CarCyDex
University College, London, Amgen
Multiple Myeloma
11/19
11/29
ACTRN12614000301662: Phase II study assessing the effect of carfilzomib treatment on early free light chain kinetics in myeloma patients with renal impairment

Completed
2
40
 
Australiasian Leukemia and Lymphoma Group, Amgen (Europe) GmbH
Multiple Myeloma with Renal Impairment
 
 
2019-001645-41: Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone vs Carfilzomib, Lenalidomide, and Dexamethasone vs Bortezomib, Lenalidomide, and Dexamethasone in Newly-Diagnosed Multiple Myeloma: A Clinical and Correlative Phase II Study

Not yet recruiting
2
462
Europe
Darzalex, Bortezomib, Dexamethasone, HUMaX-CD38, L01XX32, Dexamethasone, Capsule, hard, Powder for solution for infusion, Concentrate for solution for infusion, Powder for solution for injection, Tablet, Revlimid, Kyprolis, Darzalex, Velcade, Dexamethasone
Memorial Sloan Kettering Cancer center, Amgen
Newly diagnosed Multiple Myeloma Multipelt Myelom, Multiple Myeloma, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
ACTRN12615000818538: Single arm, multicentre study of Carfilzomib in combination with Thalidomide and Dexamethasone (CaTD) in patients with relapsed and/or refractory multiple myeloma (RRMM).

Completed
2
100
 
Australiasian Leukaemia and Lymphoma Group, Australasian Leukaemia and Lymphoma Group
Multiple Myeloma
 
 
NCT03412565: A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens

Checkmark Data from PLEIADES study for 1L newly diagnosed or rel/ref multiple myeloma at IMW 2019
Sep 2019 - Sep 2019: Data from PLEIADES study for 1L newly diagnosed or rel/ref multiple myeloma at IMW 2019
Checkmark Data from PLEIADES trial in multiple myeloma at IMW 2019
Aug 2019 - Aug 2019: Data from PLEIADES trial in multiple myeloma at IMW 2019
Completed
2
265
Europe, Japan, US, RoW
Daratumumab, Bortezomib, Lenalidomide, Dexamethasone, Melphalan, Prednisone, Carfilzomib
Janssen Research & Development, LLC
Multiple Myeloma
08/20
04/24
ACTRN12615000188538: KIWI Study- Kyprolis based Induction in untreated Myeloma with Kyprolis post Transplant Consolidation

Active, not recruiting
2
50
 
North Shore Haematology Clinical Trial Unit, Amgen Inc
Multiple Myeloma
 
 
FIL_KLIMT, NCT03891355: Carfilzomib + Lenalidomide and Dexamethasone for BTK Inhibitors Relapsed-refractory or Intolerant MCL

Active, not recruiting
2
16
Europe
Carfilzomib, Lenalidomide, Dexamethasone
Fondazione Italiana Linfomi ONLUS
Mantle Cell Lymphoma
12/20
12/22
2020-003092-18: Daratumumab in combination with Carfilzomib, Pomalidomide and Dexamethasone (DCPD) in patients with multiple myeloma inducedacute renal failure requiring dialysis - “Time Is Kidney in the Treatment of myelomA Cast nephropathy”

Ongoing
2
50
Europe
Solution for injection, Powder for solution for infusion, Capsule, hard, Tablet, DARZALEX, Kyprolis, Imnovid, Fortecortin
Medical University Innsbruck, AMGEN GmbH, Calgene GmbH, Janssen GmbH
Multiple Myeloma: Patients with MM are frequently diagnosed primarily due to renal failure. Up to 40% of the myeloma patients present with renal failure at diagnosis and approximately 10% require dialysis., Multiple Myeloma: Patients with MM are frequently diagnosed primarily due to renal failure. Up to 40% of the myeloma patients present with renal failure at diagnosis and app. 10% require dialysis., Diseases [C] - Cancer [C04]
 
 
Elo-KRd, NCT03361306: LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma

Active, not recruiting
2
15
US
Elotuzumab, Empliciti
Wake Forest University Health Sciences, Bristol-Myers Squibb, Atrium Health Levine Cancer Institute
Multiple Myeloma
06/21
02/25
CONPET, NCT03314636: Intensified Treatment With Carfilzomib in Myeloma Patients Still PET-positive After First Line Treatment.

Active, not recruiting
2
53
Europe
Carfilzomib, Lenalidomide, PET-CT, Dexamethasone
Oslo University Hospital, Nordic Myeloma Study Group
Myeloma
11/21
11/26
2021-001798-21: A Study of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma

Not yet recruiting
2
153
RoW
Magrolimab, Daratumumab, Dexamethasone, Pomalidomide, Bortezomib, carfilzomib, GS-4721, Concentrate for solution for infusion, Solution for infusion, Tablet, Capsule, hard, Powder for solution for injection, Powder for solution for infusion, Solution for injection
Gilead Sciences, Inc., Gilead Sciences, Inc.
Relapsed/Refractory Multiple Myeloma, Multiple Myeloma, Diseases [C] - Cancer [C04]
 
 
IFM 2018-04, NCT03606577: An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma Patients

Active, not recruiting
2
50
Europe
Carfilzomib, Daratumumab, Lenalidomide, Dexamethasone
Nantes University Hospital
Multiple Myeloma
02/22
11/27
12-C-0107, NCT01572480: Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma

Active, not recruiting
2
55
US
Carfilzomib, Kyprolis, Revlimid, Lenalidomide, Dexamethasone, Ozurdex
National Cancer Institute (NCI)
Multiple Myeloma
03/22
06/28
DART4MM, NCT03992170: Study of Daratumumab in Multiple Myeloma (MM) Patients in >VGPR/MRD-positive

Recruiting
2
50
Europe
Daratumumab, Darzalex
Azienda Ospedaliera Universitaria Senese, Janssen-Cilag S.p.A.
Myeloma Multiple
06/22
12/22
SKylaRk, NCT04430894: KRDI in Transplant-Eligible MM

Active, not recruiting
2
50
US
Carfilzomib, Kyprolis, Isatuximab, Sarclisa, Lenalidomide, REVLIMID, Dexamethasone, Decadron
Massachusetts General Hospital, Amgen, Sanofi
Multiple Myeloma
07/22
03/25
NCT03871829 / 2018-004185-34: Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab

Terminated
2
88
Europe, Canada, US, RoW
Carfilzomib 20 mg/m^2, Carfilzomib 70 mg/m^2, Dexamethasone 40 mg, Dara-SC 1800 mg, Dexamethasone 20 mg
Janssen Research & Development, LLC
Multiple Myeloma
10/22
01/23
NCT04191616 / 2019-001169-34: Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet

Active, not recruiting
2
54
Europe, US
Carfilzomib, Kyprolis, Dexamethasone, Decadron, Ozurdex, DexPak 6, 10, 13 Day, ReadySHarp, LoCort, Maxidex, Pomalidomide, Pomalyst
Amgen
Relapsed or Refractory Multiple Myeloma
11/22
10/24
2022-001418-20: A Study to Evaluate the Safety and Tolerability of Intravenous Modakafusp Alfa as Part of Combination Therapy in Adult Patients With Multiple Myeloma Estudio para evaluar la seguridad y la tolerabilidad de modakafusp alfa intravenoso como parte de un tratamiento combinado en pacientes adultos con mieloma múltiple

Not yet recruiting
2
144
Europe
Modakafusp Alfa, Darzalex, TAK-573, Powder for concentrate for solution for infusion, Capsule, hard, Solution for injection, Powder for solution for infusion, Zelvina 5 mg Hard Capsules, Zelvina 10 mg Hard Capsules, Imnovid 1 mg hard capsules, Imnovid 2 mg hard capsules, Imnovid 3 mg hard capsules, Imnovid 4 mg hard capsules, Bortezomib STADA 2.5 mg/ml solution for injection, Kyprolis 30 mg powder for solution for infusion, Darzalex 1800mg solution for injection
Takeda Development Center Americas, Inc., Takeda Development Center Americas, Inc.
Multiple Myeloma Mieloma múltiple, Multiple Myeloma Mieloma múltiple, Diseases [C] - Cancer [C04]
 
 
2022-002767-30: A study to investigate subcutaneous isatuximab in combination with carfilzomib and dexamethasone in adult participants with relapsed and/or refractory multiple myeloma

Not yet recruiting
2
75
RoW, Europe
isatuximab, carfilzomib, dexamethasone, SAR650984, Solution for injection, Powder for solution for infusion, Tablet, Kyprolis® 60 mg, DexaGalen®, Dexamethason 4 mg JENAPHARM®
Sanofi-aventis recherche & developpement, Sanofi-aventis recherche & developpement
Relapsed/refractory multiple myeloma (RRMM), Multiple myeloma, Diseases [C] - Cancer [C04]
 
 
2022-004207-32: Daratumumab in combination with Carfilzomib, Pomalidomide and Dexamethasone (DCPD) in patients with multiple myeloma induced acute renal failure NOT requiring dialysis

Not yet recruiting
2
50
Europe
Darzalex, Kyprolis, Imnovid, Fortecortin, Concentrate for solution for infusion, Powder for solution for infusion, Capsule, hard, Tablet, DARZALEX, Kyprolis, Imnovid, Fortecortin
Medical University Innsbruck, Internal Medicine V, AMGEN GmbH, Calgene GmbH, Janssen GmbH
Multiple Myeloma: Patients with MM are frequently diagnosed primarily due to renal failure. Patients with renal failure have a poor prognosis., Multiple Myeloma: Patients with MM are frequently diagnosed primarily due to renal failure. Patients with renal failure have a poor prognosis., Diseases [C] - Cancer [C04]
 
 
MASTER, NCT03224507: Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma

Completed
2
123
US
KRdD followed by auto-HCT, KRdD = Kyprolis (Carfilzomib), Revlimid (Lenalidomide), dexamethasone, Darzalex (Daratumumab), KRdD only
University of Alabama at Birmingham, Amgen, Janssen Scientific Affairs, LLC
Multiple Myeloma
05/23
06/23
NCT04113018: Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma

Active, not recruiting
2
39
US
Carfilzomib, lenalidomide, dexamethasone (KRd) + Daratumumab
Wake Forest University Health Sciences, Amgen, Celgene, Janssen, LP
Multiple Myeloma
06/23
10/27
NCT03155100 / 2016-001178-13: Carfilzomib + Elotuzumab + Dexamethasone for Relapsed Multiple Myeloma After 1-3 Prior Treatment Lines

Completed
2
15
Europe
Carfilzomib for Inj 60 milligram (MG), Proteasome inhibitor, Elotuzumab 400 MG, Monoclonal antibody, Dexamethasone, Steroid
Raija Silvennoinen, Amgen, Bristol-Myers Squibb, Hospital District of Helsinki and Uusimaa
Multiple Myeloma in Relapse
08/23
08/23
NCT03004287: 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy

Active, not recruiting
2
50
US
Carfilzomib, Kyprolis, Thalidomide, Thalomid, Dexamethasone, Baycadron, Daratumumab, Darzalex, Cisplatin, Platinol, Adriamycin, Doxorubicin, Cyclophosphamide, Cytoxan, Etoposide, Eposin, Melphalan, ASCT, Lenalidomide, Revlimid, Bortezomib, Velcade
University of Arkansas, Janssen, LP
Multiple Myeloma
10/24
10/25
NCT06140966: Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma

Recruiting
2
54
RoW
Daratumumab, Darzalex, Carfilzomib, Kyprolis, Lenalidomide, Revlimid, Dexamethasone, Baycadron, Cisplatin, Platinol, epirubicin, Pharmorubicin, Cyclophosphamide, Cytoxan, Etoposide, Eposin, Melphalan, Alkeran, ASCT, autologous stem cell transplantation, bortezomib, Velcade
Wuhan Union Hospital, China
Multiple Myeloma, Primary Plasma Cell Leukemia, Extramedullary Multiple Myeloma
10/26
10/27
NCT04392037: Iberdomide Combined With Low-dose Cyclophosphamide and Dexamethasone

Active, not recruiting
2
60
Europe
Iberdomide plus low-dose cyclophosphamide and dexamethasone, CC-220
Amsterdam UMC, location VUmc, Celgene
Multiple Myeloma
12/24
12/24
ASCENT, NCT03289299: Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant

Active, not recruiting
2
87
US
Carfilzomib, Lenalidomide, Daratumumab, Dexamethasone
International Myeloma Foundation, Amgen, Janssen Scientific Affairs, LLC, Celgene, Trevie, Inc.
Smoldering Multiple Myeloma
09/23
11/31
iStopMM, NCT03815279 / 2017-004785-10: A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM)

Enrolling by invitation
2
80
RoW
Carfilzomib, Kyprolis, Lenalidomide, Revlimid, Dexamethasone, Dexasone
Landspitali University Hospital, Amgen, Celgene, University of Iceland, Memorial Sloan Kettering Cancer Center
Multiple Myeloma, Smoldering Multiple Myeloma
01/24
01/28
NCT04661137: A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma

Recruiting
2
96
US
Selinexor 60 MG, KPT-330, Selinexor 80 MG, Selinexor 100 MG, Carfilzomib, Kyprolis, Pomalidomide, Pomalyst, Daratumumab, Darzalex, Dexamethasone, Dextenza, Ozurdex, Neofordex, others
Hackensack Meridian Health, Karyopharm Therapeutics Inc
Multiple Myeloma
01/25
01/25
AGMT-MM02, NCT02891811 / 2016-000475-24: Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy

Completed
2
124
Europe
Carfilzomib, Kyprolis, Thalidomide, Lenalidomide, Dexamethasone
Arbeitsgemeinschaft medikamentoese Tumortherapie, Amgen
Multiple Myeloma
03/24
03/24
NCT04176718: Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM

Recruiting
2
43
US
Daratumumab, Darzalex, Carfilzomib, Kyprolis, Pomalidomide, Pomalyst, Imnovid, Dexamethasone, Dexasone, Diodex, hexadrol
Andrew Yee, MD, Amgen, Janssen Research & Development, LLC
Multiple Myeloma, Refractory Multiple Myeloma, Multiple Myeloma in Relapse, Relapse
05/25
05/26
KMM1911, NCT05497102: Carfilzomib, Lenalidomide, and Dexamethasone Re-induction Followed by the 2nd ASCT in Multiple Myeloma Patients Relapsed After the 1st ASCT

Recruiting
2
58
RoW
Lenalidomide maintenance
Samsung Medical Center
Multiple Myeloma
05/24
12/25
SubQSA, NCT06356571: A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

Not yet recruiting
2
64
NA
Isatuximab SC-OBDS, SAR650984, Sarclisa, Montelukast, Dexamethasone, Acetaminophen, Diphenhydramine, Methylprednisolone, Carfilzomib
Sanofi
Plasma Cell Myeloma Refractory
01/27
07/27
NCT05704049: A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

Active, not recruiting
2
71
Europe, Japan, RoW
Isatuximab, Carfilzomib, Kyprolis, Dexamethasone, Dexamethasone IV, Montelukast, Acetaminophen, Diphenhydramine, Methylprednisolone
Sanofi
Relapsed/Refractory Multiple Myeloma
10/24
03/27
KMM2002, NCT05509374: Phase II Study of Carfilzomib, Pomalidomide, and Dexamethasone for Myeloma Patients Who Had Relapsed or Progressed After Carfilzomib, Lenalidomide, and Dexamethasone

Recruiting
2
33
RoW
Carfilzomib 56 MG [Kyprolis], Pomalidomide, Dexamethasone
Samsung Medical Center
Multiple Myeloma
06/24
06/24
NCT03556332: A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation

Active, not recruiting
2
41
US
Carfilzomib, Lenalidomide, Dexamethasone, Daratumumab, autologous hematopoietic cell transplantation
Memorial Sloan Kettering Cancer Center, Janssen Pharmaceuticals
Multiple Myeloma
07/25
07/25
NCT03756896: Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With High-Risk Multiple Myeloma

Active, not recruiting
2
29
US
Carfilzomib, Kyprolis, PR-171, Dexamethasone, Decadron, Dekacort, Dexameth, Hexadrol, Pomalidomide, 4-Aminothalidomide, Actimid, CC-4047, Imnovid, Pomalyst
Emory University, Amgen, National Cancer Institute (NCI), National Institutes of Health (NIH)
Plasma Cell Myeloma
03/25
03/26
HO147SMM, NCT03673826 / 2017-000555-10: Carfilzomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in High- Risk SMM

Active, not recruiting
2
58
Europe, RoW
Carfilzomib, Dexamethasone, Lenalidomide
Stichting Hemato-Oncologie voor Volwassenen Nederland
Smouldering Myeloma
08/24
12/28
NCT03290950: A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma

Active, not recruiting
2
75
US
daratumumab, carfilzomib, lenalidomide, dexamethasone, Cohort 1 administration, Cohort 2 administration
Memorial Sloan Kettering Cancer Center, Janssen Pharmaceuticals
Multiple Myeloma
09/24
09/24
NCT04756401: Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma

Recruiting
2
52
US
Carfilzomib, Kyprolis, PR-171, Daratumumab, Anti-CD38 Monoclonal Antibody, Darzalex, HuMax-CD38, JNJ-54767414, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Quality-of-Life Assessment, Quality of Life Assessment, Selinexor, ATG-010, CRM1 Nuclear Export Inhibitor KPT-330, KPT-330, Selective Inhibitor of Nuclear Export KPT-330, SINE KPT-330, Xpovio
Academic and Community Cancer Research United, National Cancer Institute (NCI)
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
09/24
12/27
NCT04925193: Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma

Recruiting
2
25
US
Selinexor, Pomalidomide, Daratumumab, Carfilzomib, Dexamethasone
University of Colorado, Denver, Karyopharm Therapeutics Inc, National Cancer Institute (NCI)
Multiple Myeloma in Relapse
11/24
11/25
GEM-KyCyDex, NCT03336073 / 2016-005008-24: Carfilzomib, Cyclophosphamide, Dexamethasone in Multiple Myeloma

Active, not recruiting
2
199
Europe
Carfilzomib, Dexamethasone, cyclophosphamide
PETHEMA Foundation
Multiple Myeloma
12/24
12/24
NCT04892446 / 2021-001798-21: Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma

Completed
2
35
Canada, US, RoW
Magrolimab, GS-4721, Daratumumab, Pomalidomide, Dexamethasone, Bortezomib, Carfilzomib
Gilead Sciences, Gilead Sciences, Inc.
Multiple Myeloma
04/24
04/24
GMMG-CONCEPT, NCT03104842 / 2016-000432-17: Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone

Checkmark Data from CONCEPT trial in combination with carfilzomib, lenalidomide, and dexamethasone for MM at ASH 2022
Dec 2022 - Dec 2022: Data from CONCEPT trial in combination with carfilzomib, lenalidomide, and dexamethasone for MM at ASH 2022
Active, not recruiting
2
246
Europe
Isatuximab, Carfilzomib, Lenalidomide, Dexamethasone
Universitätsklinikum Hamburg-Eppendorf
Multiple Myeloma
05/26
09/26
Elo-KRd, NCT02969837: Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma

Active, not recruiting
2
47
US
Elotuzumab, Empliciti, Carfilzomib, Kryprolis, Lenalidomide, Revlimid, Dexamethasone
University of Chicago, Bristol-Myers Squibb, Amgen, Multiple Myeloma Research Foundation
Multiple Myeloma
03/25
03/29
ISABEL, NCT04965155: A Trial for Relapsed Multiple Myeloma Patients (Isatuximab-dexamethasone)

Active, not recruiting
2
50
Europe
Isatuximab-dexamethasone
EMN Research Italy
Relapsed Multiple Myeloma
11/23
03/27
NCT04287855: Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma

Active, not recruiting
2
82
Europe
Isatuximab, Carfilzomib, Pomalidomide, Dexamethasone
Poitiers University Hospital, Sanofi, Celgene, Amgen, Intergroupe Francophone du Myelome
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
04/25
04/26
NCT03500445: Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma

Recruiting
2
75
US
Daratumumab, DARZALEX®, Carfilzomib, KYPROLIS®, Lenalidomide, REVLIMID®, Dexamethasone
University of Chicago, Janssen Scientific Affairs, LLC, Amgen
Myeloma, Multiple Myeloma
06/25
06/25
NCT06115135: A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma

Not yet recruiting
2
39
NA
Venetoclax, VENCLEXTA
Oncotherapeutics
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
03/26
12/26
NCT04850599: Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma

Active, not recruiting
2
5
US
Carfilzomib, Kyprolis, PR-171, Isatuximab, Hu 38SB19, Isatuximab-irfc, SAR 650984, SAR650984, Sarclisa, Pomalidomide, 4-Aminothalidomide, Actimid, CC-4047, Imnovid, Pomalyst
OHSU Knight Cancer Institute, Oregon Health and Science University, Sanofi
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
04/26
02/29
NCT05669989: International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab

Recruiting
2
70
Europe, Japan, US, RoW
Isatuximab intravenous (IV), SARCLISA®, SAR650984, Cemiplimab (SAR439684), Dexamethasone, Lenalidomide, Pomalidomide, Isatuximab subcutaneous (SC), Carfilzomib
Sanofi
Plasma Cell Myeloma
11/26
11/26
NCT04933539: Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma

Active, not recruiting
2
11
US
Dexamethasone, Carfilzomib, Daratumumab
National Cancer Institute (NCI), Janssen Scientific Affairs, LLC
Multiple Myeloma
04/25
10/32
NCT04268498: A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma

Recruiting
2
306
Europe, US
Bortezomib, Dexamethasone, Lenalidomide, Revlimid, Acetaminophen, Diphenhydramine, Montelukast, Carfilzomib, Daratumumab, Autologous Stem Cell Transplant (ASCT)
University of Miami, Amgen, Janssen Pharmaceuticals
Multiple Myeloma
02/27
02/27
NCT02899052 / 2019-004340-30: Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)

Checkmark Data in MM at ASCO 2018
May 2018 - May 2018: Data in MM at ASCO 2018
Active, not recruiting
2
120
Europe, US, RoW
Carfilzomib, Kyprolis, Venetoclax, Venclexta, ABT-199, Dexamethasone
AbbVie, Genentech, Inc; Onyx Therapeutics, Inc.
Multiple Myeloma
06/27
06/27
KMM-KCd, NCT05909826: Carfilzomib, Oral Cyclophosphamide, and Dexamethasone for RRMM

Not yet recruiting
2
49
NA
Carfilzomib, Kyprolis, Cyclophosphamide, Alkyloxan, Dexamethasone
Dong-A University Hospital
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
06/27
06/27
REACH, NCT05497804: Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, Trial

Recruiting
2
75
US
Bone Marrow Aspiration and Biopsy, Carfilzomib, Kyprolis, PR-171, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, tomography, Daratumumab, Darzalex, HuMax-CD38, JNJ-54767414, Daratumumab Biosimilar HLX15, Daratumumab-fihj, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Magnetic Resonance Imaging, Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning
Mayo Clinic, National Cancer Institute (NCI)
ISS Stage III Plasma Cell Myeloma, Multiple Myeloma
11/27
11/28
NCT04263480: Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia

Recruiting
2
99
Europe
Carfilzomib + Ibrutinib, Ibrutinib
Christian Buske, Amgen, Janssen, LP
Waldenstrom Macroglobulinemia
02/28
02/28
IRB22-1781, NCT05789303: Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma

Recruiting
2
83
US
Belantamab mafodotin, Blenrep, Carfilzomib, Kyprolis, Pomalidomide, Pomalyst, Dexamethasone
University of Chicago, GlaxoSmithKline, Amgen
Multiple Myeloma, Relapse Multiple Myeloma
07/28
07/28
Iber-KDd, NCT05896228: Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone () in Patients With Relapsed/Refractory Multiple Myeloma

Recruiting
2
30
US
Iberdomide, Carfilzomib, Daratumumab, Dexamethasone, Acetaminophen, Diphenhydramine, Montelukast
Carl Ola Landgren, MD, PhD, Bristol-Myers Squibb
Refractory Multiple Myeloma, Relapsed Multiple Myeloma
03/29
03/31
NCT04883242: Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

Recruiting
2
37
US
Carfilzomib, Kyprolis, PR-171, Carfilnat, CFZ, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Isatuximab, Hu 38SB19, Isatuximab-irfc, SAR 650984, SAR650984, Sarclisa, SAR-650984, Pomalidomide, 4-Aminothalidomide, Actimid, CC-4047, Imnovid, Pomalyst, CC4047, Bone Marrow Biopsy, Bone Marrow Aspiration, Skeletal Survey X-Ray, Computed Tomography, CAT Scan, Computed Axial Tomography, Positron Emission Tomography, PET scan, Magnetic Resonance Imaging, MRI
University of Washington, Genzyme, a Sanofi Company
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
12/29
12/29
NCT01665794: Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Checkmark ASCO 2016
May 2016 - May 2016: ASCO 2016
Recruiting
1b/2
101
Canada, US
Pomalidomide, CC-4047, Pomalyst(R), Carfilzomib, Kyprolis (R), PR-171, dexamethasone, Aeroseb-Dex, Decaderm, Decadron, DM, DXM, Daratumumab, Daralex
University of Chicago, National Cancer Institute (NCI), Multiple Myeloma Research Foundation
Multiple Myeloma
11/24
11/24
ACTRN12620000490976p: A phase I/II single arm study of combination Belantamab Mafodotin, Carfilzomib, Dexamethasone in patients with early relapsed multiple myeloma

Not yet recruiting
1/2
70
 
Australasian Myeloma Research Consortium , GlaxoSmithKline Australia Pty Ltd
Multiple Myeloma
 
 
NCT01857115: Study of Weekly Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients (wCCyd)

Active, not recruiting
1/2
63
Europe
Carfilzomib, Krypolis, Cyclophosphamide, Endoxan, Dexamethasone, Decadron
Stichting European Myeloma Network, Fondazione EMN Italy Onlus
Multiple Myeloma
11/13
09/24
NCT02204241: Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients

Completed
1/2
36
Europe
Carfilzomib, Cyclophosphamide, Dexamethasone
European Myeloma Network, Fondazione EMN Italy Onlus
Multiple Myeloma
06/15
04/23
NCT02185820: Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed And/Or Refractory Multiple Myeloma Patients (CPD)

Completed
1/2
57
Europe
Carfilzomib, Pomalidomide, Dexamethasone
European Myeloma Network, University of Turin, Italy
Multiple Myeloma
07/15
01/23
NCT02056756: Carfilzomib In Combination With Bendamustine And Dexamethasone In Refractory Or Relapsed Multiple Myeloma

Completed
1/2
63
Europe
Carfilzomib, Krypolis
Stichting European Myeloma Network, Fondazione EMN Italy Onlus
Multiple Myeloma
09/15
01/23
NCT02073097: Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma

Completed
1/2
48
US
Carfilzomib, Kyprolis, PR-171, Rituximab, IDEC-C2B8, IDEC-C2B8 monoclonal antibody, Mabthera, MOAB IDEC-C2B8, Rituxan, Cyclophosphamide, CPM, CTX, Cytoxan, Endoxan, Endoxana, Doxorubicin hydrochloride, ADM, ADR, Adria, Adriamycin PFS, Adriamycin RDF, Vincristine sulfate, leurocristine sulfate, VCR, Vincasar PFS, Prednisone, DeCortin, Deltra, Pegfilgrastim, Neulasta, Recombinant methionyl human granulocyte colony-stimulating factor (G-CSF), Acyclovir, Zovirax
Case Comprehensive Cancer Center
Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma
07/21
06/23
2021-002125-15: Study for the treatment of relapsed myeloma patients, refractory to lenalidomide Estudio para el tratamiento de pacientes con mieloma múltiple en recaída y refractario a lenalidomida

Ongoing
1/2
60
Europe
Belantamab mafodotina, Carfilzomib, GSK2857916, Injection/infusion, BLENREP, KYPROLIS
Fundación Pethema, Fundación Pethema
myeloma multiple mieloma múltiple, myeloma multiple mieloma múltiple, Diseases [C] - Cancer [C04]
 
 
2021-006038-37: A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-573 in Participants With Refractory Multiple Myeloma

Not yet recruiting
1/2
336
Europe
Modakafusp Alfa, TAK-573, Powder for concentrate for solution for infusion
Takeda Development Center Americas, Inc., TAKEDA DEVELOPMENT CENTER AMERICAS INC., Takeda Development Center Americas, Inc.
Relapsed/Refractory Multiple Myeloma, Multiple Myeloma, Diseases [C] - Cancer [C04]
 
 
BuMelCarAuto, NCT03795597: Busulfan, Melphalan, Escalating Carfilzomib Conditioning Auto Stem Cell Transplantation for Multiple Myeloma (MM)

Recruiting
1/2
36
US
Carfilzomib, Kyprolis, Busulfan IV, Busulfex, Melphalan IV, Alkeran
Loyola University, Amgen
Multiple Myeloma
11/22
11/23
NCT03773107: LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma

Completed
1/2
12
US
Carfilzomib, Kyprolis, Ruxolitinib, Jakafi, Dexamethasone
Wake Forest University Health Sciences, Incyte Corporation, Multiple Myeloma Research Consortium, Amgen
Multiple Myeloma
11/22
02/24
ACTRN12620000490976: A phase I/II single arm study of combination Belantamab Mafodotin, Carfilzomib, Dexamethasone in patients with early relapsed multiple myeloma

Active, not recruiting
1/2
68
 
Australasian Myeloma Research Consortium , GlaxoSmithKline Australia Pty Ltd
Multiple Myeloma
 
 
NCT02937571: High Dose Carfilzomib for Newly Diagnosed Myeloma

Active, not recruiting
1/2
37
US
Carfilzomib, Lenalidomide, Dexamethasone
Memorial Sloan Kettering Cancer Center, Onyx/Amgen, Celgene
Multiple Myeloma
10/24
10/24
QUAD, NCT01297764: A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma

Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Active, not recruiting
1/2
17
US
Vorinostat, Lenalidomide, Carfilzomib, Dexamethasone, Vorinostat (Zolinza), Lenalidomide (Revlimid), Carfilzomib (Kyprolis), Dexamethasone (Decadron, Baycadron)
Hackensack Meridian Health
Multiple Myeloma
11/24
11/24
CC-92480-MM-002, NCT03989414 / 2018-004767-31: A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

Active, not recruiting
1/2
424
Europe, Canada, US, RoW
CC-92480, BMS-986348, mezigdomide, Bortezomib, Dexamethasone, Daratumumab, Carfilzomib, Elotuzumab, Isatuximab
Celgene
Multiple Myeloma
11/26
11/26
ADAPT, NCT05017545: Carfilzomib and Belatacept for Desensitization

Recruiting
1/2
15
US
carfilzomib, Kyprolis®, belatacept, Nulojix®, Bone marrow aspiration
National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network (ITN), Bristol-Myers Squibb, PPD, Rho Federal Systems Division, Inc.
Highly Sensitized Prospective Kidney Transplant Recipients
02/27
02/28
GEM-BELMA, NCT05060627 / 2021-002125-15: Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to Lenalidomide

Recruiting
1/2
60
Europe
Belantamab mafodotin, Carfilzomib, Dexamethasone
PETHEMA Foundation, Adknoma Health Research
Relapsed Multiple Myeloma
05/24
05/28
NCT04822337: Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma

Recruiting
1/2
70
US
Carfilzomib, Lenalidomide, Dexamethasone, Belantamab Mafodotin
Wake Forest University Health Sciences, Amgen, GlaxoSmithKline
Multiple Myeloma
10/24
10/24
STOMP, NCT02343042: Selinexor and Backbone Treatments of Multiple Myeloma Patients

Checkmark From STOMP trial in combination with Pomalyst & low dose dexamethasone for r/r multiple myeloma
Jun 2021 - Jun 2021: From STOMP trial in combination with Pomalyst & low dose dexamethasone for r/r multiple myeloma
Checkmark Data from STOMP trial in combination with lenalidomide and dexamethasone for multiple myeloma at ASH 2020
Dec 2020 - Dec 2020: Data from STOMP trial in combination with lenalidomide and dexamethasone for multiple myeloma at ASH 2020
Checkmark Data from STOMP trial in combination with carfilzomib and dexamethasone for multiple myeloma at ASH 2020
More
Active, not recruiting
1/2
300
Canada, US
Selinexor, KPT-330, XPOVIO®, Dexamethasone, Decadron®, Lenalidomide, Revlimid®, Pomalidomide, Pomalyst®, Bortezomib, Velcade®, Daratumumab, Darzalex®, Carfilzomib, Kyprolis®, Ixazomib, Ninlaro®, Elotuzumab, Empliciti®, Clarithromycin, Biaxin, Belantamab Mafodotin, BLENREP, Mezigdomide, BMS-986348, CC-92480
Karyopharm Therapeutics Inc, Bristol-Myers Squibb
Multiple Myeloma
04/27
04/27
NCT04764942: Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial

Recruiting
1/2
81
US
Carfilzomib, Carfilnat, CFZ, Kyprolis, PR-171, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Pomalidomide, 4-Aminothalidomide, Actimid, CC-4047, Imnovid, Pomalyst, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Selinexor, ATG-010, CRM1 Nuclear Export Inhibitor KPT-330, KPT-330, Selective Inhibitor of Nuclear Export KPT-330, SINE KPT-330, Xpovio, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, X-Ray, Plain film radiographs, Radiographic Imaging, Static X-Ray, X-Ray, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, CT, CT Scan, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography Scan, Positron-Emission Tomography, Proton magnetic resonance spectroscopic imaging, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Bone Marrow Aspiration, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Blood Sample Collection
Mayo Clinic, National Cancer Institute (NCI)
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
03/25
03/26
NCT05199311: Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma

Suspended
1/2
66
US
Carfilzomib, Iberdomide, Oral Dexamethasone
Hackensack Meridian Health
Multiple Myeloma
11/25
11/25
COMMANDER, NCT05434689: COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide

Recruiting
1/2
80
US
Iberdomide, Daratumumab, Dexamethasone, Carfilzomib
University of Alabama at Birmingham
Multiple Myeloma
12/25
10/26
 

Download Options